ACLY and metabolic dysfunction-associated steatotic liver disease: Another potential pathway implicated in MASLD pathogenesis is hepatic lipogenesis mediated by the SLC13A5/SLC25A1 ACLY-dependent signaling pathway, as described by Sun et al. [84].